SOFT and TEXT: Trials of tamoxifen and exemestane with and without ovarian function suppression for premenopausal women with hormone receptor -positive early breast cancer

被引：0
|
作者：
Zickl, L.
Francis, P.
Fleming, G.
Pagani, O.
Walley, B.
Price, K. N.
Gelber, R. D.
Regan, M. M.
机构：
来源：
CANCER RESEARCH | 2012年 / 72卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT2-2-01
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor positive (HR plus ) early breast cancer (BC): Update of the combined TEXT and SOFT trials
    Pagani, Olivia
    Regan, Meredith M.
    Fleming, Gini F.
    Walley, Barbara A.
    Colleoni, Marco
    Lang, Istvan
    Gomez, Henry L.
    Tondini, Carlo
    Burstein, Harold J.
    Goetz, Matthew P.
    Ciruelos, Eva M.
    Stearns, Vered
    Debled, Marc
    Martino, Silvana
    Geyer, Charles E., Jr.
    Pinotti, Graziella
    Coates, Alan S.
    Goldhirsch, Aron
    Gelber, Richard D.
    Francis, Prudence A.
    [J]. CANCER RESEARCH, 2018, 78 (04)
  • [2] Randomized comparison of adjuvant aromatase inhibitor exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR plus ) early breast cancer (BC): update of the combined TEXT and SOFT trials
    Regan, Meredith M.
    Walley, Barbara A.
    Fleming, Gini F.
    Francis, Prudence A.
    Colleoni, Marco A.
    Lang, Istvan
    Gomez, Henry L.
    Tondini, Carlo A.
    Burstein, Harold J.
    Goetz, Matthew P.
    Ciruelos, Eva M.
    Stearns, Vered
    Bonnefoi, Herve R.
    Martino, Silvana
    Geyer, Charles E., Jr.
    Chini, Claudio
    Minisini, Alessandro M.
    Spazzapan, Simon
    Ruhstaller, Thomas
    Winer, Eric P.
    Ruepp, Barbara
    Loi, Sherene
    Coates, Alan S.
    Goldhirsch, Aron
    Gelber, Richard D.
    Pagani, Olivia
    [J]. CANCER RESEARCH, 2022, 82 (04)
  • [3] Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor-Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Tamoxifen in the Suppression of Ovarian Function Trial (SOFT): The SOFT-EST Substudy
    Bellet, Meritxell
    Gray, Kathryn P.
    Francis, Prudence A.
    Lang, Istvan
    Ciruelos, Eva
    Lluch, Ana
    Angel Climent, Miguel
    Catalan, Gustavo
    Avella, Antoni
    Bohn, Uriel
    Gonzalez-Martin, Antonio
    Ferrer, Roser
    Catalan, Roberto
    Azaro, Analia
    Rajasekaran, Agnita
    Morales, Josefa
    Vazquez, Josep
    Fleming, Gini F.
    Price, Karen N.
    Regan, Meredith M.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (14) : 1584 - U89
  • [4] Adjuvant Ovarian Function Suppression in Premenopausal Hormone Receptor-Positive Breast Cancer
    Basmadjian, Robert B.
    Lupichuk, Sasha
    Xu, Yuan
    Quan, May Lynn
    Cheung, Winson Y.
    Brenner, Darren R.
    [J]. JAMA NETWORK OPEN, 2024, 7 (03) : E242082
  • [5] Role of obesity on the efficacy of exemestane plus ovarian suppression in hormone receptor-positive premenopausal breast cancer
    Sendur, Mehmet Ali Nahit
    Aksoy, Sercan
    Akinci, Muhammed Bulent
    Ozdemir, Nuriye
    Dede, Didem Sener
    Altundag, Kadri
    Zengin, Nurullah
    Yalcin, Bulent
    [J]. FUTURE ONCOLOGY, 2015, 11 (06) : 905 - 907
  • [6] Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer
    Lambertini, Matteo
    Viglietti, Giulia
    de Azambuja, Evandro
    [J]. CURRENT OPINION IN ONCOLOGY, 2019, 31 (01) : 43 - 51
  • [7] The Role of Ovarian Suppression in Premenopausal Women With Hormone Receptor-Positive Early-Stage Breast Cancer
    Jain, Sarika
    Santa-Maria, Cesar Augusto
    Gradishar, William J.
    [J]. ONCOLOGY-NEW YORK, 2015, 29 (07): : 473 - +
  • [8] Duration of ovarian function suppression for premenopausal women with hormone receptor-positive breast cancer: Retrospective study
    Ozaki, Y.
    Tamura, N.
    Utiyama, M.
    Masuda, J.
    Koganemaru, S.
    Miura, Y.
    Tanabe, Y.
    Ogura, T.
    Kadowaki, M.
    Miura, D.
    Kawabata, H.
    Takano, T.
    [J]. CANCER RESEARCH, 2016, 76
  • [9] Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials
    Bernhard, Juerg
    Luo, Weixiu
    Ribi, Karin
    Colleoni, Marco
    Burstein, Harold J.
    Tondini, Carlo
    Pinotti, Graziella
    Spazzapan, Simon
    Ruhstaller, Thomas
    Puglisi, Fabio
    Pavesi, Lorenzo
    Parmar, Vani
    Regan, Meredith M.
    Pagani, Olivia
    Fleming, Gini F.
    Francis, Prudence A.
    Price, Karen N.
    Coates, Alan S.
    Gelber, Richard D.
    Goldhirsch, Aron
    Walley, Barbara A.
    [J]. LANCET ONCOLOGY, 2015, 16 (07): : 848 - 858
  • [10] Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women
    Lu, Yen-Shen
    Wong, Andrea
    Kim, Hee-Jeong
    [J]. FRONTIERS IN ONCOLOGY, 2021, 11
12345